We are a novel drug R&D company focusing on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. With a team of around 200 scientists and staff, our pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and China. These products include a novel oral therapy for inflammatory bowel disease, which is Phase III for UC (ulcerative colitis) in the US & Europe; a novel oral selective c-Met inhibitor in phase II in Australia, China & the United States; four differentiated oral NCEs in oncology in Phase I & Phase II in China; and one oral NCE for inflammation in Phase I in Australia. Multiple NCEs are also in preclinical development. In September 2012, Elsevier Business Intelligence and the BayHelix Group announced that they awarded prizes to celebrate innovation in China, during an awards ceremony luncheon at the PharmAsia Summit in Shanghai. Awards recipients were selected from a list of nominees submitted by members of the China and global pharmaceutical community. The Alliance of the Year award recognizes a ground breaking pharmaceutical collaboration agreement involving a Chinese entity.